The benchmark Sensex settled at 74,151 on Thursday, setting the stage for four healthcare counters to touch their 52-week price peaks. Shukra Medtech and Acutaas Chemicals led the monthly advance with gains reaching up to 26% and 24% respectively. Meanwhile, Piramal Pharma and Laurus Labs both advanced by approximately 12% over the same monthly timeframe. Notably, Laurus Labs concluded trading right at its newly established peak of Rs 2,245.
Key points
Heightened investor activity lifted multiple healthcare stocks to their highest trading l…: Heightened investor activity lifted multiple healthcare stocks to their highest trading levels in 12 months.
Laurus Labs demonstrated notable strength by finishing the trading day exactly at its pea…: Laurus Labs demonstrated notable strength by finishing the trading day exactly at its peak of Rs 2,245.
Both Piramal Pharma and Laurus Labs mirrored each other with monthly gains of approximate…: Both Piramal Pharma and Laurus Labs mirrored each other with monthly gains of approximately 12%.
Sources checked by our analysis pipeline: 1
On Thursday, the benchmark Sensex surged 905 points to close at 74,151. Amid the market rally, four stocks from the BSE Healthcare index touched fresh 52-week highs, reaching their highest levels in the past year. A 52-week high marks the highest price at which a stock has traded over the preceding 12 months and may reflect increased market activity and investor interest.
TIL Creatives
2/5
Shukra Medtech (Shukra Pharmaceuticals)
New 52-week high: Rs 79.9| CMP: Rs 74.99. In the last one month stock has gained about 26%.
Agencies
3/5
Acutaas Chemicals
New 52-week high: Rs 4031.85| CMP: Rs 3981.55. In the last one month stock has gained about 24%.
ETMarkets.com
4/5
Piramal Pharma
New 52-week high: Rs 239.4| CMP: Rs 230.6. In the last one month stock has gained about 12%.
5/5
Laurus Labs
New 52-week high: Rs 2245| CMP: Rs 2245. In the last one month stock has gained about 12%.
Wall Street analysts are growing increasingly cautious about Google's core revenue engine amid shifting consumer engagement patterns. Financial institutions are concerned that commercial returns are failing to keep pace with the sheer volume of search activity. This trend threatens to compress margins as infrastructure expenses climb without an equivalent rise in ad conversions.
Market participants responded favorably to a dual catalyst of stronger-than-expected financial results and a formal rating adjustment. BNP Paribas improved its stance on the firm as reported earnings surpassed prior targets. This combination spurred renewed buying interest, driving the equity higher in recent trading sessions.
Investor sentiment turned negative across major exchanges following the tech giant's latest financial update. Market participants are growing increasingly anxious about the massive capital expenditures required to develop advanced technology, leading to an immediate pullback during the morning session.